Study of the expression of scFv anti-KLK3 antibodies in bacteria
The development of biopharmaceuticals gained notoriety with the use of recombinant DNA, revolutionizing the process of biopharmaceuticals, having several advantages such as the reduction of side effects in patients. KLK3 is a proteolytic enzyme belonging to the group of 15 enzymes called KLK1-15 related to body homeostasis and various diseases. Also known as PSA, KLK3 is related to prostate cancer, where its serum level is increased, with this, it is possible to use this enzyme as a biomarker of prostate cancer. The present work tests a selection of bivalent antibody fragments of the scFv-Fc type against the KLK3 enzyme in prokaryotic cells, which may be used, in the future, for the detection of PSA.